Clinical Research DirectorSanofi, Cambridge, MA, USACambridge, Massachusetts, United States
OC 01.4 - Interim analysis of joint outcomes in adult and adolescent patients with severe hemophilia A receiving efanesoctocog alfa during the phase 3 XTEND-ed long-term extension study
Saturday, June 22, 202413:45 – 14:00 ICT
OC 14.1 - Perioperative management with efanesoctocog alfa in adults, adolescents, and children with severe hemophilia A in the phase 3 XTEND clinical program
Sunday, June 23, 202409:30 – 09:45 ICT
